Erasca extends cash runway to H2 2025, accelerates naporafenib and ERAS-601 readouts

Erasca, Inc.

Cash runway extended from H1 2025 to H2 2025; resources focused on naporafenib and ERAS-007/601 sub-studies.
SEACRAFT-1 (naporafenib in RAS Q61X solid tumors) data readout accelerated to Q2-Q4 2024 from H2 2024-H1 2025.
FLAGSHP-1 (ERAS-601 in HPV-neg HNSCC) data readout accelerated to H1 2024 from calendar year 2024.
HERKULES-3 (ERAS-007/601 in BRAFm CRC) data readout affirmed for H2 2023-H1 2024.
Other milestones: SEACRAFT-2 Ph3 FPD in NRASm melanoma H1 2024, THUNDERBBOLT-1 Ph1 data in rGBM H2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.